Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brandon Miller

Showing results (21-30 of 26) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 26 results.
Cancer Chemotherapy and Pharmacology|November 27, 2023
Pharmacodynamic effects of the PARP inhibitor talazoparib (MDV3800, BMN 673) in patients with BRCA-mutated advanced solid tumorsArjun Mittra, Geraldine H O' Sullivan Coyne, Jennifer Zlott, et al.
JCO Precision Oncology|July 16, 2025
Safety and Tolerability of Berzosertib, an Ataxia-Telangiectasia-Related Inhibitor, and Veliparib, an Oral Poly (ADP-ribose) Polymerase Inhibitor, in Combination With Cisplatin in Patients With Refractory Solid TumorsGeraldine O'Sullivan Coyne, Khanh T Do, Shivaani Kummar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 19, 2025
A Phase I Study of Nilotinib in Combination with Paclitaxel in Patients with Advanced Solid TumorsSarah J Shin, Geraldine O'Sullivan Coyne, Shivaani Kummar, et al.
Cancer Chemotherapy and Pharmacology|March 14, 2026
Phase I trial of the combination of bortezomib and clofarabine in adults with refractory tumorsJibran Ahmed, Andre DeSouza, Shivaani Kummar, et al.
Cancer Chemotherapy and Pharmacology|April 22, 2020
Intravenous 5-fluoro-2'-deoxycytidine administered with tetrahydrouridine increases the proportion of p16-expressing circulating tumor cells in patients with advanced solid tumorsGeraldine O 'Sullivan Coyne, Lihua Wang, Jennifer Zlott, et al.
ACS Infectious Diseases|October 11, 2023
Shotgun Kinetic Target-Guided Synthesis Approach Enables the Discovery of Small-Molecule Inhibitors against Pathogenic Free-Living Amoeba GlucokinasesMintesinot Kassu, Prakash T Parvatkar, Jillian Milanes, et al.
Pageof 3

Showing results (21-30 of 26) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 26 results.
Cancer Chemotherapy and Pharmacology|November 27, 2023
Pharmacodynamic effects of the PARP inhibitor talazoparib (MDV3800, BMN 673) in patients with BRCA-mutated advanced solid tumorsArjun Mittra, Geraldine H O' Sullivan Coyne, Jennifer Zlott, et al.
JCO Precision Oncology|July 16, 2025
Safety and Tolerability of Berzosertib, an Ataxia-Telangiectasia-Related Inhibitor, and Veliparib, an Oral Poly (ADP-ribose) Polymerase Inhibitor, in Combination With Cisplatin in Patients With Refractory Solid TumorsGeraldine O'Sullivan Coyne, Khanh T Do, Shivaani Kummar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 19, 2025
A Phase I Study of Nilotinib in Combination with Paclitaxel in Patients with Advanced Solid TumorsSarah J Shin, Geraldine O'Sullivan Coyne, Shivaani Kummar, et al.
Cancer Chemotherapy and Pharmacology|March 14, 2026
Phase I trial of the combination of bortezomib and clofarabine in adults with refractory tumorsJibran Ahmed, Andre DeSouza, Shivaani Kummar, et al.
Cancer Chemotherapy and Pharmacology|April 22, 2020
Intravenous 5-fluoro-2'-deoxycytidine administered with tetrahydrouridine increases the proportion of p16-expressing circulating tumor cells in patients with advanced solid tumorsGeraldine O 'Sullivan Coyne, Lihua Wang, Jennifer Zlott, et al.
ACS Infectious Diseases|October 11, 2023
Shotgun Kinetic Target-Guided Synthesis Approach Enables the Discovery of Small-Molecule Inhibitors against Pathogenic Free-Living Amoeba GlucokinasesMintesinot Kassu, Prakash T Parvatkar, Jillian Milanes, et al.
Pageof 3